HIGH-RISK INDUSTRY
Specialized payment processing for peptides, SARMs, and research-use-only (RUO) compound retailers and manufacturers. Direct relationships with acquiring banks that have committed to the research compound category long-term.
WHY ITS HIGH-RISK
Peptide and SARM retailers operate in one of the most regulatory-complex categories in commerce. The FDA has not approved most peptides and SARMs for human consumption, requiring operators to position products as research-use-only (RUO). This RUO classification creates significant processor caution because of the gap between how products are marketed and how customers actually use them. Mainstream processors like Stripe, Square, and PayPal blanket-ban the peptides and SARMs category as a policy decision. The result is predictable. Peptide and SARM operators face account terminations without warning when processors update their acceptable use policies. Even properly compliant RUO businesses with clear research-only marketing get caught in category exits. New operators struggle to find any mainstream processor willing to take them on. Established peptide brands with years of clean processing history can lose accounts during portfolio reviews when a single news story triggers processor risk policy changes. Green Financial works with acquiring banks that have specifically underwritten the peptide and SARM category and understand the RUO regulatory framework. Our work in this space covers peptide retailers, SARM operators, research compound businesses, and the broader research-use-only market across direct-to-consumer and B2B research supply channels.
INTEGRATIONS
Direct integration with major payment gateways and the ecommerce platforms that connect to them. If you're running something custom, we likely support that too.
WHAT YOU GET
Green Financial places you with the right acquiring bank, then stays involved to help you keep the account running. Here's how the work breaks down.
01 - PLACEMENT
We get you to the right acquirer.
Green Financial places your business with one of the acquiring banks that have committed to underwriting peptides, SARMs, and research-use-only compounds. The bank holds your merchant account; we get you to them and advocate for your application through underwriting.
02 - APPLICATION
We make your case to the bank.
Peptide and SARM merchant account underwriting requires demonstrating proper RUO positioning, product sourcing, lab testing documentation, and clear marketing compliance. We package your application with the regulatory documentation, business operations, and processing context the bank needs to approve you, then submit and follow up on the file throughout review.
03 - GATEWAY
Your processing infrastructure, ready to go.
Once your merchant account is approved, we set up your gateway account with the appropriate provider (typically Authorize.net, NMI, or USAePay depending on your business model) and send you the invitation to access your dashboard. From there, your API keys and platform integration are yours to manage with your developer or directly.
04 - ONGOING SUPPORT
Real people when something goes wrong.
After your account is live, you have direct access to our team for questions, account issues, processing concerns, or escalations with your acquiring bank or gateway. We stay involved as your business grows and your processing needs change.
05 - GUIDANCE
Plain-language answers when you need them.
Peptide and SARM businesses face regulatory questions that mainstream processors won't engage with. We offer plain-language guidance on RUO marketing requirements, FDA considerations, lab testing standards, customer disclosure practices, and the operational decisions that affect your relationship with your acquiring bank.
06 - GROWTH
More processing capacity when you need it.
As your business grows, we help you add merchant accounts for redundancy or higher volume, navigate processor changes if your bank exits the category, and expand into related services through our network including business funding and B2B BNPL through Adrodex.
WHO WE WORK WITH
HOW IT WORKS
All accounts approved within 7 days. Most in 1-2 business days.
FREQUENTLY ASKED
Direct answers to the questions we hear most from peptide and SARM operators exploring high-risk payment processing.
All accounts approved within one week. For peptide and SARM businesses with documented RUO positioning and lab testing, typical approval timelines run 3-5 business days. Newer operators or businesses without lab testing documentation may take the full week as bank compliance completes review.
Yes. Green Financial works with peptide and SARM businesses at all stages, including pre-launch operations and startups that haven’t processed their first transaction. Documented product sourcing, lab testing, and proper RUO marketing positioning help significantly with underwriting approval for new operators.
In most cases, yes. Mainstream processors terminate peptide and SARM accounts solely because of the category, not because of specific business problems. We place you with an acquiring bank that has committed to the research compound category. If you were placed on MATCH, placement is still typically possible but may take a week or more.
Yes. Peptide and SARM products that are not FDA-approved for human consumption must be marketed as research-use-only (RUO). This means no human consumption claims, no dosing recommendations, no medical claims, and clear labeling and website disclaimers. Acquiring banks underwriting this category require demonstrated RUO compliance during application review and ongoing operations.
No. Peptide and SARM processing rates run higher than low-risk categories because acquiring banks price the regulatory complexity into their fees, but Green Financial doesn’t take advantage of merchants who don’t have many options. We’ll match or beat the pricing you had with your previous processor.
Yes. Peptide and SARM operators with consistent revenue often qualify for business funding through our financing partners, including inventory financing for product brands, equipment financing for lab and manufacturing operations, and unsecured lines of credit for working capital.
